SenesTech received a notification from Nasdaq on July 31, 2024, regarding non-compliance with audit committee requirements following the departure of Delphine François Chiavarini from the board and audit committee on July 11, 2024. The company no longer meets Nasdaq's requirement of having at least three independent directors on its audit committee.Nasdaq has granted SenesTech a cure period until the earlier of their next annual stockholders' meeting or July 11, 2025, to regain compliance. If the next annual meeting occurs before January 7, 2025, the company must demonstrate compliance by January 7, 2025. The notification has no immediate impact on SenesTech's Nasdaq Capital Market listing.The company is actively seeking a qualified independent board member who meets the audit committee criteria and intends to utilize the cure period to restore compliance. However, there is no guarantee of regaining or maintaining compliance with Nasdaq's continued listing requirements.

SenesTech received a notification from Nasdaq on July 31, 2024, regarding non-compliance with audit committee requirements following the departure of Delphine François Chiavarini from the board and audit committee on July 11, 2024. The company no longer meets Nasdaq's requirement of having at least three independent directors on its audit committee.Nasdaq has granted SenesTech a cure period until the earlier of their next annual stockholders' meeting or July 11, 2025, to regain compliance. If the next annual meeting occurs before January 7, 2025, the company must demonstrate compliance by January 7, 2025. The notification has no immediate impact on SenesTech's Nasdaq Capital Market listing.The company is actively seeking a qualified independent board member who meets the audit committee criteria and intends to utilize the cure period to restore compliance. However, there is no guarantee of regaining or maintaining compliance with Nasdaq's continued listing requirements.